| AMERISOURCEBERGEN-HEALTH-CORPORATION |
AMERISOURCEBERGEN-HEALTH-CORPORATION |
92%
|
Significant Customers We had three wholesalers each comprising 10 percent or more of our total revenue for the year ended December 31, 2024: McKesson Drug Company, Cardinal Health, Inc. and Amerisour… |
| MCKESSON-DRUG-COMPANY |
MCKESSON-DRUG-COMPANY |
92%
|
Significant Customers We had three wholesalers each comprising 10 percent or more of our total revenue for the year ended December 31, 2024: McKesson Drug Company, Cardinal Health, Inc. and Amerisour… |
| GQ-BIO-THERAPEUTICS-GMBH |
GQ-BIO-THERAPEUTICS-GMBH |
85%
|
evelopment of PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like OA… |
| JNJ |
Johnson & Johnson |
85%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from PCRX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from PCRX graph: Reciprocal relationship from JNJ grap… |
| JNJ |
Johnson & Johnson |
85%
|
025, of which $ million are due in each of 2026 and 2027, $ million in 2028, and $ million in each of 2028 and 2029. The Company has $ million of other minimum, non-cancelable contractual commitments… |
| AVNS |
Avanos Medical, Inc. |
72%
|
Reciprocal relationship from AVNS graph: Reciprocal relationship from PCRX graph: Reciprocal relationship from AVNS graph: Reciprocal relationship from PCRX graph: Reciprocal relationship from AVNS g… |
| AVNS |
Avanos Medical, Inc. |
72%
|
ers of EXPAREL, ZILRETTA or iovera° that accounted for 10 percent or more of our total revenue for the year ended December 31, 2025. Manufacturing and Research Facilities Internal Facilities We manuf… |
| CAH |
Cardinal Health, Inc. |
72%
|
Reciprocal relationship from CAH graph: Reciprocal relationship from PCRX graph: s of the partnership, LG Chem has the exclusive rights to commercialize EXPAREL in the region. We received a $2.0 mill… |
| CAH |
Cardinal Health, Inc. |
72%
|
s of the partnership, LG Chem has the exclusive rights to commercialize EXPAREL in the region. We received a $2.0 million upfront payment that we will recognize over the license term upon commerciali… |
| HRTX |
Heron Therapeutics, Inc. |
72%
|
Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multi… |
| ORANY |
ORANY |
72%
|
ers of EXPAREL, ZILRETTA or iovera° that accounted for 10 percent or more of our total revenue for the year ended December 31, 2025. Manufacturing and Research Facilities Internal Facilities We manuf… |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from PCRX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from PCRX graph: Reciprocal relationship from ORAN… |
| AMERISOURCEBERGEN-HEALTH-CORPORATION-CARDINAL-HE |
AMERISOURCEBERGEN-HEALTH-CORPORATION-CARDINAL-HE |
62%
|
s With Customers The Company’s net product sales consist of (i) EXPAREL in the U.S., European Union, or E.U., and the U.K.; (ii) ZILRETTA in the U.S.; (iii) iovera° in the U.S., Canada and Europe and… |
| ARATANA-THERAPEUTICS-INC |
ARATANA-THERAPEUTICS-INC |
62%
|
-facing team, consisting of sales representatives, account managers, scientific and medical affairs personnel and reimbursement and market access professionals, executes on a full range of activities… |
| CARLISLE-COMPANIES-INC |
CARLISLE-COMPANIES-INC |
62%
|
ZILRETTA or iovera° accounted for 10 percent or more of our total revenue for the year ended December 31, 2024. Manufacturing and Research Facilities Internal Facilities We manufacture EXPAREL and io… |
| ELANCO-ANIMAL-HEALTH-INC |
ELANCO-ANIMAL-HEALTH-INC |
62%
|
-facing team, consisting of sales representatives, account managers, scientific and medical affairs personnel and reimbursement and market access professionals, executes on a full range of activities… |
| FURTHER-PACIRA-BIOSCIENCES-INC |
FURTHER-PACIRA-BIOSCIENCES-INC |
62%
|
uently suspended for 30 days in order to facilitate negotiations. As of the date of this Annual Report, the proposed tariffs on all imports from Mexico remain suspended. Our iovera° tips are made in … |
| IT-PACIRA-BIOSCIENCES-INC |
IT-PACIRA-BIOSCIENCES-INC |
62%
|
on. PCRX-201 is the lead program from this platform. It Pacira BioSciences, Inc. | 2024 Annual Report on Form 10-K | Page 75 Table of Contents provides financial benefits with the elimination of futu… |
| JIANGSU-HENGRUI-PACIRA-BIOSCIENCES-INC |
JIANGSU-HENGRUI-PACIRA-BIOSCIENCES-INC |
62%
|
ZILRETTA or iovera° accounted for 10 percent or more of our total revenue for the year ended December 31, 2024. Manufacturing and Research Facilities Internal Facilities We manufacture EXPAREL and io… |
| KNEE-OA-GENASCENCE-CORPORATION |
KNEE-OA-GENASCENCE-CORPORATION |
62%
|
he strategic investments we have made to support promising early-stage platforms are summarized below: Company Development Stage Description of Platform Technology Potential Therapeutic Areas Carthro… |
| KNEE-OA-SPINE-BIOPHARMA-LLC |
KNEE-OA-SPINE-BIOPHARMA-LLC |
62%
|
he strategic investments we have made to support promising early-stage platforms are summarized below: Company Development Stage Description of Platform Technology Potential Therapeutic Areas Carthro… |
| MCKESSON-DRUG-COMPANY-CARDINAL-HEALTH-INC |
MCKESSON-DRUG-COMPANY-CARDINAL-HEALTH-INC |
62%
|
elivering a validatable manufacturing process and validated analytical control package necessary for initiating process validation. In February 2025, Pacira Therapeutics, Inc., a wholly-owned subsidi… |
| OYSTER-ACQUISITION-COMPANY-INC |
OYSTER-ACQUISITION-COMPANY-INC |
62%
|
-facing team, consisting of sales representatives, account managers, scientific and medical affairs personnel and reimbursement and market access professionals, executes on a full range of activities… |
| PLATFORM-TECHNOLOGY-POTENTIAL-THERAPEUTIC-AREAS- |
PLATFORM-TECHNOLOGY-POTENTIAL-THERAPEUTIC-AREAS- |
62%
|
he strategic investments we have made to support promising early-stage platforms are summarized below: Company Development Stage Description of Platform Technology Potential Therapeutic Areas Carthro… |
| POSTOPERATIVE-OPIOID-PACIRA-BIOSCIENCES-INC |
POSTOPERATIVE-OPIOID-PACIRA-BIOSCIENCES-INC |
62%
|
osomal Bupivacaine on Postoperative Opioid Pacira BioSciences, Inc. | 2024 Annual Report on Form 10-K | Page 9 Table of Contents Prescribing After Third Molar Extraction , was published in The Journa… |
